Signal Explorer
10-K · 10-Q · 8-K · last 6 months · ← back to feed
Septerna, Inc.
SEPN
Core
Clinical Trial Result
Lead Asset Progress
Clinical Hold
Combination Therapy Mentioned
Indication Expansion
Secondary Endpoint Mentioned
Other
Enrollment Ahead Of Schedule
Patient Retention High
Interim Data Positive
Safety Differentiated
Fda Aligned
Fast Track Granted
Protocol Amended
Fast Track Designation Received
Biotech v3
Ai Drug Discovery Investment